The lack of randomized trials comparing new bladder cancer drugs to the standard of care, gemcitabine-docetaxel, isn't just about cost. There's an underlying fear within pharmaceutical companies that their expensive new agents may not prove superior to the highly effective and inexpensive 'gemdose,' stalling meaningful progress.
Despite distinct FDA approval pathways for CIS and papillary bladder cancer, clinicians widely treat them as the same disease. This leads to routine off-label use of drugs approved for CIS in patients with papillary-only disease, highlighting a gap between regulatory frameworks and real-world clinical practice.
The efficacy of new bladder cancer drugs in single-arm trials is hard to assess because of concurrent improvements in surgical technology. Modern scopes allow for more complete resection of CIS tumors, meaning a "complete response" may be due to the surgery before the drug is even administered, not the drug itself.
Despite being a superior visualization tool for bladder cancer, blue light cystoscopy's adoption is shockingly low. This is partly due to a widely cited but flawed UK trial that created an intellectual barrier, alongside modest financial hurdles for community practices.
The effective, inexpensive standard of care, gemcitabine-docetaxel ('gemdose'), is rarely used in US community practices because it is unprofitable. Clinicians openly admit to choosing more expensive, reimbursed drugs to maintain financial viability, creating a stark divide with academic centers.
Initially intended to fill a therapeutic void, the FDA's pathway for single-arm trials in BCG-unresponsive bladder cancer has led to numerous approvals. This success has created a new problem: a crowded market of expensive drugs with weak comparative data, making rational treatment selection difficult.